In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Novavax, Inc (NASDAQ: NVAX) closed at $8.25 in the last session, up 0.73% from day before closing price of $8.19. In other words, the price has increased by $0.73 from its previous closing price. On the day, 3.68 million shares were traded.
Ratios:
We take a closer look at NVAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.93 and its Current Ratio is at 0.93.
BofA Securities Upgraded its Underperform to Neutral on May 10, 2024, whereas the target price for the stock was revised from $4 to $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when King Rachel K. sold 4,150 shares for $9.02 per share. The transaction valued at 37,435 led to the insider holds 14,770 shares of the business.
YOUNG JAMES F sold 5,400 shares of NVAX for $43,200 on Dec 31 ’24. The Director now owns 51,760 shares after completing the transaction at $8.00 per share. On Dec 24 ’24, another insider, YOUNG JAMES F, who serves as the Director of the company, sold 4,600 shares for $8.48 each. As a result, the insider received 39,008 and left with 57,160 shares of the company.
Stock Price History:
Over the past 52 weeks, NVAX has reached a high of $23.86, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is -5.45%, while the 200-Day Moving Average is calculated to be -26.86%.
Shares Statistics:
A total of 160.15M shares are outstanding, with a floating share count of 146.11M. Insiders hold about 8.79% of the company’s shares, while institutions hold 60.08% stake in the company.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Novavax, Inc (NVAX) in the stock market.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.49 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.14 and -$1.83 for the fiscal current year, implying an average EPS of -$1.45. EPS for the following year is $0.2, with 6.0 analysts recommending between $2.35 and -$1.65.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $90.92M. It ranges from a high estimate of $103.6M to a low estimate of $83.3M. As of the current estimate, Novavax, Inc’s year-ago sales were $291.34MFor the next quarter, 4 analysts are estimating revenue of $47.5M. There is a high estimate of $47.5M for the next quarter, whereas the lowest estimate is $47.5M.
A total of 6 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $718.12M, while the lowest revenue estimate was $673.9M, resulting in an average revenue estimate of $688.56M. In the same quarter a year ago, actual revenue was $983.71MBased on 6 analysts’ estimates, the company’s revenue will be $561.48M in the next fiscal year. The high estimate is $1.03B and the low estimate is $227.92M.
